Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leiomyoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1Adenomyosis 1

Interventions

Cyclophosphamide 16Vincristine 12Prednisone 11Methotrexate 11Etoposide 9Cytarabine 9merphos 8blinatumomab 8venetoclax 7prednylidene 7pegaspargase 7deltacortene 7Specimen Handling 7Mercaptopurine 7Dexamethasone 7azathiopurine 6N,N-dicyclohexyl-isoborneol-10-sulfonamide 6Doxorubicin 6Calcium Dobesilate 6dexamethasone acetate 5dexamethasone 21-phosphate 5auricularum 5Spinal Puncture 5Rituximab 5Leucovorin 5Biopsy 5fludarabine phosphate 4Stem Cell Transplantation 4Methylprednisolone 4Inotuzumab Ozogamicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Burkitt Lymphoma × Triamcinolone × Clear all
NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
22 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmSarcoma

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡